Uric Acid Lowering and Biomarkers of Kidney Damage in CKD Stage 3: A Post Hoc Analysis of a Randomized Clinical Trial.

ABSTRACT:

Rationale & objective

Hyperuricemia is associated with chronic kidney disease (CKD) progression. We evaluated whether lowering serum uric acid levels improves levels of biomarkers of kidney damage.

Study design

Post hoc analysis of clinical trial participants.

Setting & participants

A double-blind randomized placebo-controlled study designed to lower serum uric acid levels. 80 patients with stage 3 CKD and asymptomatic hyperuricemia were randomly assigned to allopurinol treatment or placebo (300 mg/d) for 12 weeks.

Exposure/predictor

Allopurinol treatment versus placebo.

Outcomes & measures

We evaluated the change from baseline for the following urinary biomarkers of kidney damage: albumin-creatinine ratio (ACR), neutrophil gelatinase-associated lipocali

SUBMITTER: Perrenoud L 

PROVIDER: S-EPMC7487946 | biostudies-literature | 2020 Mar-Apr

REPOSITORIES: biostudies-literature